MediWound (MDWD) Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MDWD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MediWound Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$12.78 |
| Beta | 0.36 |
| 1 Month Change | 20.94% |
| 3 Month Change | 27.58% |
| 1 Year Change | 26.76% |
| 3 Year Change | 68.62% |
| 5 Year Change | 60.71% |
| Change since IPO | -82.13% |
Recent News & Updates
MediWound Ltd: Undervalued High Growth Potential
May 16We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth
May 14
Recent updates
MediWound Ltd: Undervalued High Growth Potential
May 16We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth
May 14What You Can Learn From MediWound Ltd.'s (NASDAQ:MDWD) P/S
Apr 18
FDA Approval And Phase III Trial Will Expand Wound Care
Strong EscharEx results and strategic partnerships boost potential sales growth, leveraging Medicare policies and Phase III trials for greater revenue prospects.Is MediWound (NASDAQ:MDWD) In A Good Position To Invest In Growth?
Feb 12MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable
Jan 09Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts
Nov 29MediWound Is A Healthy Investment
Oct 29Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher
Jul 23Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%
May 07We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
Feb 28Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking
Feb 01MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up
Dec 18MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Sep 29MediWound's NexoBrid for thermal burns in children gets EMA review
Sep 20Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates
Aug 11MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
Aug 09MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review
Aug 03MediWound adds 13% after favorable data for ulcer candidate
Jul 07MediWound taps Tzvi Palash as COO
Jun 30Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?
Jun 24Shareholder Returns
| MDWD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.6% | 2.1% | 1.8% |
| 1Y | 26.8% | -9.7% | 12.6% |
Return vs Industry: MDWD exceeded the US Pharmaceuticals industry which returned -10.1% over the past year.
Return vs Market: MDWD exceeded the US Market which returned 11% over the past year.
Price Volatility
| MDWD volatility | |
|---|---|
| MDWD Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: MDWD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDWD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 111 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. Fundamentals Summary
| MDWD fundamental statistics | |
|---|---|
| Market cap | US$234.20m |
| Earnings (TTM) | -US$21.22m |
| Revenue (TTM) | US$19.21m |
Is MDWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDWD income statement (TTM) | |
|---|---|
| Revenue | US$19.21m |
| Cost of Revenue | US$16.45m |
| Gross Profit | US$2.77m |
| Other Expenses | US$23.99m |
| Earnings | -US$21.22m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 14.39% |
| Net Profit Margin | -110.45% |
| Debt/Equity Ratio | 0% |
How did MDWD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/06 19:09 |
| End of Day Share Price | 2025/06/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediWound Ltd. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| David Maris | BMO Capital Markets Equity Research |
| Jason Wittes | Brean Capital |